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Abstract
Background: This study aimed to quantify structural and functional changes at the macula during acute exposure to high
altitude and to assess their structure/function relationship. This work is related to the Tuebingen High Altitude
Ophthalmology (THAO) study.
Methodology/Principal Findings: Spectral domain optical coherence tomography and microperimetry were used to
quantify changes of central retinal structure and function in 14 healthy subjects during acute exposure to high altitude
(4559 m). High-resolution volume scans and fundus-controlled microperimetry of the posterior pole were performed in
addition to best-corrected visual acuity (BCVA) measurements and assessment of acute mountain sickness. Analysis of
measurements at altitude vs. baseline revealed increased total retinal thickness (TRT) in all four outer ETDRS grid subfields
during acute altitude exposure (TRTouter=2.8061.00 mm; mean change695%CI). This change was inverted towards the
inner four subfields (TRTinner=21.8960.97 mm) with significant reduction of TRT in the fovea (TRTfoveal=26.6260.90 mm) at
altitude. BCVA revealed no significant difference compared to baseline (0.0660.08 logMAR). Microperimetry showed stable
mean sensitivity in all but the foveal subfield (MSfoveal=21.1260.68 dB). At baseline recordings before and .2 weeks after
high altitude exposure, all subjects showed equal levels with no sign of persisting structural or functional sequels.
Conclusions/Significance: During acute exposure to high altitude central retinal thickness is subject to minor, yet
statistically significant changes. These alterations describe a function of eccentricity with an increase in regions with
relatively higher retinal nerve fiber content and vascular arcades. However, these changes did not correlate with measures
of central retinal function or acute mountain sickness. For the first time a quantitative approach has been used to assess
these changes during acute, non-acclimatized high altitude exposure.
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Introduction
Retinal hypoxia is a common pathogenetic mechanism in highly
prevalent disorders of vision loss such as diabetic retinopathy,
central or branch retinal vein occlusion or less prevalent forms of
small vessel disease [1]. Regardless of its upstream etiology, retinal
hypoxia upregulates expression of a number of factors including
vascular endothelial growth factor (VEGF), which in turn causes
increased vascular permeability and downstream retinal edema
formation [2]. In line with this concept, increased levels of VEGF
have been found in diabetic retinopathy with increased vascular
leakage [3,4]. Furthermore, both supplemental inspired oxygen
[5] and pharmacologic inhibition of VEGF [6] have been shown
to effectively decrease retinal thickness in existing diabetic macular
edema. In venous occlusive disorders, steroids such as triamcin-
olone have been found to exact their therapeutic effect on
reducing/reversing retinal edema formation in part by down-
regulation of VEGF expression [7]. These findings all support the
notion that retinal oxygenation levels play an important role in the
maintenance of retinal structure and function and that pathologic
levels of hypoxia may result in disruption of the brain-retina-
barrier (BRB) with resulting macular edema and disturbances of
visual function. This aspect might bear its greatest relevance in the
delicate microenvironment of the central retina with its foveal
avascular zone and its exceeding importance for key functional
tasks such as daylight visual acuity. Indeed, there is robust
evidence for changes in central retinal function in response to
different oxygenation levels even in healthy subjects both at sea
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36155level [8,9] and during exposure to altitude related hypoxia [10–
12]. Alterations in central retinal function such as visual acuity,
retinal sensitivity and color vision can potentially have deleterious
effects especially in mountaineering, where visual orientation,
reading instruments and maps can become a life-saving necessity.
Detailed quantitative analyses of macular changes at high altitude
might be difficult to perform due to unique logistic challenges.
Some studies circumvented this problem by recording changes
several days after the exposure to altitude [13–16]. However,
measurements acquired any time after descent may not reflect the
changes during acute exposure to high altitude related hypoxia.
The research facilities at Capanna Margherita (4559 m, Italy) and
readily available helicopter service provide ideal logistical solutions
to such an undertaking with the additional benefit of an
established ascent profile already used in other studies on high
altitude medicine especially in regard to acute mountain sickness
[17–19]. Our study aimed to precisely quantify changes of central
retinal structure and function during acute exposure of healthy
volunteers to high altitude using state of the art technology
including Spectralis
TM HRA+OCT and fundus-controlled micro-
perimetry. In addition these changes were correlated with
measures of acute mountain sickness to test a possible causative
link.
Methods
Study design
A total of fourteen healthy subjects ascended to the Capanna
Margherita (CM; Valais Alps, Italy) according to a previously
published ascent profile [19] (Fig. 1): day 0 from Gressoney (Italy)
1635 m to Punta Indren 3260 m by cable car followed by 2 hours
(hr) of hiking to the Capanna Gnifetti 3647 m; day 1 ascent to the
CM 4559 m in 4–6 hr. All subjects ascended within 24 hr from
Gressoney to the CM and spent three nights (from day 1 to day 4)
at the CM before descending back to Gressoney on day 4. Before
baseline recordings (BL1= before and BL2= after the climb) and
ascent, subjects had to spend .14 days below 2000 m to exclude
confounding effects due to previous altitude exposure. All subjects
were healthy and physically fit (7 females, 7 males; age 25–
54 years). Clinical assessment of acute mountain sickness (AMS)
and vital parameters was performed as previously published [19].
Briefly, Lake-Louise (LL) and AMS-cerebral score (AMS-c) of the
Environmental Symptom Questionnaire (ESQ III) were used to
assess prevalence of AMS defined as LL $5 in the presence of
headache and AMS-c$0.70 [20].
Ophthalmological exclusion criteria were presence of disorders
affecting the macular region, best corrected visual acuity (BCVA)
.0.3 (logMAR) on either eye and/or optical opacities limiting
imaging quality. Macular structure was analyzed on all days (BL1,
day 1–4 and BL2) in all but one subject: Unfortunately, one male
subject had an incomplete data set at BL1 and was therefore
excluded from further analysis; all subjects underwent BCVA
assessment on BL1, day 1–3 and BL2 and microperimetry was
performed on BL1, day 1, day 3 and BL2. The study was
performed in accordance with the tenets of the Declaration of
Helsinki 1975 (1983 revision) and was approved by the local IRB
(Ethik-Kommission der Medizinischen Fakulta ¨t und am Universi-
ta ¨tsklinikum Tuebingen, IEC project number: 258/2010B01). All
subjects gave written informed consent after having been informed
of the nature of the research expedition. All equipment was
transported by helicopter (Air Zermatt AG Heliport, Zermatt,
Switzerland) in airfreight containers provided by the manufac-
turers.
Visual Acuity
Freiburg Visual Acuity Test (FrACT, http://michaelbach.de/
fract/) was used to measure BCVA according to published
guidelines [21,22]. Briefly, Landolt-C optotypes were displayed on
a daily re-calibrated computer monitor (SyncMaster 204B,
Samsung Electronics GmbH, Schwallbach, Germany), for self-
paced measurement of visual acuity. In this EN ISO 8596
compliant visual test battery, subjects respond by pressing one of 8
buttons (eight alternative forced choice task) to indicate the
orientation of the gap in the Landolt-C. The next optotype is
presented based on integration of previous responses applying the
best Probability Estimation of Sensory Threshold (best PEST)
strategy [23]. A total of 18 trials are run to estimate the acuity
threshold, which is defined as 56.25% (the middle between 100%
and the guessing rate 12.5%).
Spectral Domain Optical Coherence Tomography
To quantitatively measure the changes of the central retinal
tissue two identical Spectralis
TM HRA+OCT (Heidelberg Engi-
neering, Heidelberg, Germany) devices were used for the baseline
measurements and for the measurements at altitude as previously
described [24,25]. Briefly, pupillary mydriasis was induced in
subjects using tropicamide eye drops 5 mg/ml (Mydriaticum
Figure 1. Ascent profile of subjects to the Capanna Margherita (4559 m). Symbols indicate times of measurements performed at high
altitude:
{OCT;
1Microperimetry;
{BCVA; OCT = optical coherence tomography; BCVA = best corrected visual acuity.
doi:10.1371/journal.pone.0036155.g001
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scans centered on the fovea were recorded with a scan pattern of
30625u with 31 B-Scans at 245 mm intervals. To triple signal to
noise ratio, 9 scans were averaged while correcting for eye
movements using the proprietary TruTrack
TM function. To
ensure comparability of iterative measurements by correcting for
errors such as tilt and orientation, we exported the data from the
baseline recordings performed at the University Eye Hospital
Tuebingen in the proprietary format (.E2E) and imported it prior
to follow-up measurements at altitude. Careful calibration of the
laser light source of the Spectralis
TM HRA+OCT device was
performed after re-assembling at altitude to ensure comparability
of measurements. According to the manufacturers instructions
(Instructions for the Spectralis Installation Report, Heidelberg
Engineering), power of the OCT light source, a superluminescent
diode (SLD), was measured at the outlet of the camera using
a special adapter provided by Heidelberg Engineering (Sensor
PD300, Heidelberg Engineering) and a Ophir powermeter (Nova
Powermeter, Spiricon GmbH, Ahrensburg, Germany) set for a test
wavelength of 880 nm and range of 3 mW. In the IR/OCT
mode, IR-laser was set to 0% laser power using the touch panel
service mode and SLD power was measured directly at the
objective using the circular ring scan (no laser modulation) at 30u
field view. Measurements of SLD laser power both at BL1-2 and
at altitude were 1.22 mW. Subsequently, we ensured optical
alignment of the spectrometer and compared the SLD spectra in
the OCT service screen, which displays a one-line detector output
(A-Scan image). Manipulation of the cable loom allowed to ‘‘fine
tune’’ the height of the spectrum as this depends to some extent on
polarization effects. This provided an almost identical shape of the
spectral curve and height of the maximum between both locations
of measurement and thus ensured comparability of measurements.
Built-in software (Eye Explorer v1.6.4.0 and Spectralis Viewing
Module 5.3.2.0) was used to calculate interpolated retinal thickness
values (Fig. 2A) using the default macular subfield analysis
(ETDRS grid) in reference to the early treatment of diabetic
retinopathy study (ETDRS)[26].
Microperimetry
Fundus controlled microperimetry was performed using two
identical Nidek MP1 (NAVIS software version 1.7.4.B1; Nidek
Technologies) devices. Chen et al. have previously published test-
retest variability, which was applied in this study [27]. Briefly, both
pupils were dilated as described above before microperimetry was
performed first on the right, then on the left eye while the
respective contralateral eye was patched. Microperimetry was
conducted in a darkened room. A 2u red cross was used as the
fixation target. Real-time correction of involuntary eye movements
was achieved by initial co-registration of high-contrast landmarks
in the infrared fundus image by the operator. All subjects initially
underwent brief training allowing familiarization and practice with
correct operation of the response trigger and the stimulus target.
This was followed by the first test protocol featuring a white test
stimulus of Goldmann III equivalent size (0.4u) with 200 ms
duration. Stimulus was presented at 68 loci in a grid covering the
central 20u manually centered on the fovea (Fig. 2B). To reduce
testing time, a pre-test protocol was programed to present initial
6 dB stimuli at four parafoveal loci. A 4 to 2 staircase strategy was
used (as in the following testing protocol) to determine retinal
threshold. These values were then used as the starting brightness
for testing retinal mean sensitivity (MS) in the remaining,
randomly tested loci. The refinement and re-check option was
not used.
Multimodal Mapping
Co-registration of high-resolution OCT volume scans and
microperimetry data was performed using a custom-made
software tool (MultiModalMapper)[28] as previously published
[29]. Briefly, co-registration of the coordinate systems of micro-
perimetry and OCT datasets was based on an affine trans-
formation model, which mapped microperimetry data (source
coordinate system) on OCT data (target coordinate system) based
on corresponding landmarks manually set on both co-recorded
fundus images. After co-registration, the same ETDRS grid
algorithm was used to calculate interpolated MS values from test
loci within each grid compartment (Fig. 2C). This allowed
accurate definition of functional output originating from each
Figure 2. Protocols used to analyze central retinal structure and function in one subject at baseline (BL1). A) Pseudo-colored heatmap
diagram indicates total retinal thickness (mm) in a 25630u volume OCT scan centered on the fovea (color coding scale at bottom). B) Pseudo-colored
retinal sensitivity (dB) results in 68 loci within the central 20u projected on the infrared fundus image after co-registration (color coding scale at
bottom). C) Multimodal mapping approach of structural/functional data and its analysis in nine distinct ETDRS subfields (dimensions indicated
below).
doi:10.1371/journal.pone.0036155.g002
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and function in the macular region.
Statistical Methods
JMPH was used for statistical analysis (Version 8.0.2, SAS
Institute, Cary, NC). As measurements of the left and right eye
revealed no significant differences (see results section), only the
right eye was considered. Furthermore, as measurements at
baseline (BL1-2) and at altitude (day 1–4) provided consistent
levels respectively, we calculated the mean differences between
baseline recordings (BL1-2) and measurements at altitude (mean
day 1–4) for a descriptive comparison. Statistical longitudinal
analysis was achieved by multivariate analysis of variance
(MANOVA) for repeated measures. Data are shown in terms of
intra-individual differences (value during exposure – value at BL1)
and the 95% confidence limits for each time point. Pearson’s
correlation coefficient was calculated to evaluate a possible
correlation between retinal thickness measures and functional
data (MS) per ETDRS grid compartment.
Results
All 14 subjects successfully ascended to the CM and completed
all examinations during 4 days at high altitude as noted in Figure 1.
In this cohort, incidence of AMS was 64% on day 1 and
prevalence decreased in the following days as expected with
acclimatization. Accordingly, AMS-c scores and heart rate
reached highest levels on day 1 after arrival at CM, whereas
oxygen saturation was expectably decreased (see table 1) with
overall lower but non-significant changes in AMS positive subjects.
Statistical analysis of all data sets on retinal structure and
function showed no statistical difference between baseline record-
ings before and after acute exposure to high altitude (BL1 vs. BL2),
thus indicating the stability of our baseline recordings and the
reversibility of any changes associated with high altitude exposure.
Furthermore, there were no statistically significant differences
between data from the right and the left eyes of subjects.
Therefore, we decided to consider only data from right eyes as
a rather conservative measure to minimize false positive findings.
SD-OCT volume scans of the central retina showed significant
changes with a gradient from the foveal center to the more
peripheral areas of the macula. While the foveal ETDRS subfield
demonstrated a noteworthy reduction of TRT at altitude (mean of
day 1–4) compared to baseline recordings (TRTfoveal=–
6.6260.90 mm; mean695%CI), the neighboring inner ETDRS
subfields showed only minimal changes (TRTinner=–
1.8961.93 mm). In contrast, TRT was increased in the outer
ETDRS subfields (TRTouter=2.8061.99 mm) at altitude vs.
baseline. Statistical longitudinal analysis (MANOVA) reflected
the difference between recordings at baseline and altitude and
demonstrated rather stable readings at both settings, i.e. there was
only limited variability during day 1–4 and between measure-
ments at BL1 vs. 2 (Fig. 3, data are summarized in table 2).
Functional test results displayed stable performance throughout
the study with no significant mean differences in BCVA
measurements between recordings at baseline and altitude
(logMAR =–0.0660.08 dB, detailed longitudinal data are
displayed in Fig. 4A). Topographic analysis of retinal sensitivity
was performed using the fundus-controlled microperimetry on
day 1 and day 3 at high altitude. In line with stable BCVA
measurements, all ETDRS grid subfields maintained stable mean
retinal MS compared to baseline values. Statistical longitudinal
analysis (Fig. 4B–C) relvealed one exception regarding the foveal
subfield at day3 (MSfoveal=–1.3861.12 dB) but not on day 1
(MSfoveal=–0.8560.92 dB). The full functional data set is
summarized in table 3 and table 4.
Co-registration of the structural and functional data in the
MultiModalMapper software allowed testing for topographically
related association of structural and functional changes at altitude.
Pearson’s correlation analysis between MS and TRT values from
foveal, inner and outer ETDRS subfields showed no statistical
significant association (p .0.05, see table S1).
As previous studies have provided equivocal results regarding
a correlation between AMS and ocular changes under hypoxia
and/or at high altitude [19,30–35], we calculated the association
between AMS-c, heart rate or SpO2 and changes of retinal
structure (TRT) in foveal, inner or outer ETDRS subfields. There
was no significant correlation between TRT values of any subfield
and AMS-c (p .0.05). For clinical parameters no significant
correlation was found for heart rate (p .0.05). Only SpO2
correlated significantly with TRT values of the foveal (r=0.61,
p=0.03) and inner (r=0.66, p=0.01), but not the outer subfields
(see table S2).
Discussion
This study was undertaken to objectively quantify structural and
functional changes in the central retina during acute high altitude
exposure as hypoxic challenge. The human macula is a highly
specialized region at the posterior pole of ca. 3 mm diameter
(foveal and inner ETDRS subfields), which relays crucial visual
information such as daylight visual acuity. It features some
anatomic peculiarities compared to the rest of the retina, which
convey increased optical resolution peaking in the rod free foveola.
Most notably, retinal vessels and nerve fiber bundles circumvent
the macula in superior and inferior arcades to minimize light
scatter in the center (outer ETDRS subfields). The central foveal
region is completely avascular and thus dependent on diffusion of
Table 1. Overview of acute mountain sickness (AMS) related parameters.
BL1 1 late 2 early 2 late 3 early 3 late 4 early BL2
AMS [%] 0 64 50 29 21 0 14 0
AMS-c [score] 0 1.0260.65 1.0760.74 0.7060.68 0.6560.81 0.2560.33 0.3360.36 0
LL [score] 0 5.3662.21 5.3662.59 3.9362.09 4.0063.37 2.0761.54 2.4362.14 0
Heart rate [min-1] 60.467.35 88.4365.97 83.43610.12 82.7169.45 77.14612.18 75.22616.60 73.64613.43 58.1466.92
SpO2 [%] 98.5061.34 69.3664.36 72.1465.86 74.4367.07 73.9366.04 76.7863.83 79.3664.31 98.2961.27
data are mean6standard deviation; n=14; AMS-c = acute mountain sickness cerebral score; LL = Lake Louise; SpO2 = oxygen saturation by pulse oximetry; late = c.
21 h; early = c. 6 h.
doi:10.1371/journal.pone.0036155.t001
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retina) and a surrounding capillary network (inner retina) [36]. As
a result, especially its inner retinal neurons are prone to ischemic
conditions and there is abundant evidence for secondary structural
and functional changes in the macula e.g. due to diabetic small
vessel disease, smoking or other factors, which affect oxygen
transport to this avascular neuronal tissue [1,5,8,9]. This is also
reflected by the definition of clinically significant macular edema
(CSME) [26], which calls for retinal thickening and/or hard
exudates with adjacent retinal thickening within 500 mm of the
macular center (foveal ETDRS subfield) or one or more disc
diameters of retinal thickening, part of which needs to be within
one disc diameter of the macular center (inner ETDRS subfields).
As acute exposure to high altitude was expected to challenge
this delicate microenvironment in the foveal avascular zone, we
initially speculated on a hypoxia mediated increase in central
retinal thickness, possibly with some reduction of functional
measures. However, while changes in TRT during acute exposure
to high altitude related hypoxia demonstrated robust significance
levels especially in the foveal and outer ETDRS subfields, this was
largely due to the exceptionally low test-retest variability of the
Spectralis
TM HRA+OCT [37,38]. The limited relative change of
TRT at altitude in all ETDRS subfields clearly demonstrates, that
Figure 3. Structural changes at the posterior pole during acute exposure to high altitude in healthy subjects. A–I) Intraindividual
changes (expressed as differences: baseline-altitude) of total retinal thickness within ETDRS subfields show decreased total retinal thickness (TRT) in
the foveal and inner subfields and an increased TRT in outer subfields. Red dashed lines indicate BL1 level; center of diamonds represent mean, top
and bottom horizontal lines indicate the 95% confidence interval, whiskers indicate standard error and horizontal lines display standard deviation;
n=13.
doi:10.1371/journal.pone.0036155.g003
Table 2. Changes (intra-individual differences) of total retinal thickness (TRT) in all ETDRS subfields at all time-points.
foveal outer-nasal inner-nasal outer-superior inner-superior outer-temporal inner-temporal outer-inferior inner-inferior
BL1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
day1 –6.0862.38 2.4662.56 –1.1563.19 2.6963.23 –0.0862.80 3.3162.57 –2.3162.09 3.1562.33 –0.8562.74
day2 –6.6261.91 2.3861.52 –2.6262.18 2.3862.34 –0.8561.67 2.2361.91 –3.4661.01 2.9262.19 –2.3861.63
day3 –8.0061.64 2.6262.76 –3.2362.22 2.2362.47 –1.9261.97 2.0861.77 –4.0861.45 2.7762.08 –2.6962.23
day4 –5.7761.75 3.9261.89 –0.6262.51 1.6961.57 0.2361.66 3.8561.69 –2.1561.67 4.0861.65 –2.0861.77
BL2 –0.7761.48 –1.0861.65 –0.3162.44 1.0062.27 –0.3862.35 2.6962.19 –1.8561.54 0.8562.12 –0.3161.47
Longitudinal intra-individual changes of total retinal thickness in all nine ETDRS subfields at each time-point as difference from baseline (BL1).
ETDRS = early treatment of diabetic retinopathy; BL= baseline; data are displayed as mean695% confidence interval in mm; n=13.
doi:10.1371/journal.pone.0036155.t002
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a superior dynamic range of autoregulatory counter mechanisms
within the macular region to meet the demands of oxygenation
even under conditions of acute exposure to high altitude related
hypoxia in healthy subjects. However, exposure to higher altitudes
and/or longer duration of altitude related hypoxia may have
a more deleterious effect and can not be ruled out by this study.
Interestingly, outer ETDRS subfields showed limited, but
significant increase in TRT. This paramacular area features an
inherently higher relative content of retinal nerve fiber bundles
and retinal vessels. As previous studies at very high (ca. 8000 m)
and high altitude (ca. 4500 m) have provided evidence for
increased thickness of retinal nerve fibers and dilated, tortuous
retinal vessels, it seems plausible to assume this as a contributing
factor for the relative increase in TRT in the outer ETDRS
subfields [13,19,30,33]. One previous OCT study on retinal
changes associated with high altitude exposure and acute
mountain sickness showed no significant alteration in any of the
ETDRS subfields [13]. However, subjects in this study were
examined at an altitude of 247 m two weeks before and after
returning from the expeditions in the Himalayas. Given the
minute absolute changes of retinal thickness to be expected, we
argue that lack of significant findings in this previous study might
be attributed to its study design. In fact, our baseline recordings
were recorded similarly, i.e. $ two weeks prior and after acute
exposure to high altitude and showed no statistical significant
difference. In contrast, recordings at altitude provided evidence for
small, yet statistically significant changes of TRT in ETDRS
subfields when compared to these baseline recordings. Correlation
analyses between TRT changes in ETDRS subfields and AMS-c
showed no significant association. Of clinical parameters associ-
ated with AMS severity, only SpO2 demonstrated a significant
correlation with TRT of foveal and macular but not paramacular
subfields. This lack of robust association between ocular changes
and AMS parameters is in line with previous observations that
AMS occurs independently of optic disc edema formation [19],
but contrasts reports on significant correlations between AMS vs.
optic disc swelling, increased optic nerve sheath diameter,
increased corneal thickness or increased retinal capillary blood
flow [30,31,33,34]. Part of the discrepancy can be explained by
differences in ascent profiles, absolute altitude, duration of altitude
exposure, methods of data acquisition (e.g. qualitative vs.
quantitative) and examination protocol (i.e. recording at altitude
vs. after descent). Here, we see a major strength of our study
design, which used an established ascent profile and relied on state
of the art quantitative diagnostic instruments, which are routinely
used in clinical ophthalmology. This is intended to facilitate
comparability with future studies and help to relate the observed
changes with clinical findings in prevalent pathologic ischemic
conditions. Our study design relied on the known and exception-
ally low test-retest variability of the Spectralis
TM HRA+OCT
[37,38]. But even though all our data – including published results
in this Journal [19] – point towards the notion that all structural
changes in the eye are completely reversible, iterative recordings
before exposure (BL1) rather then comparison of baseline
recordings (BL1 vs. BL2) would have additionally strengthened
Figure 4. Functional changes at the retinal center during acute exposure to high altitude in healthy subjects. A) Intraindividual
changes (expressed as differences: baseline-altitude) of best corrected visual acuity (BCVA in logMAR) and B–J) retinal mean sensitivity (MS in dB)
values for each ETDRS subfield show no significant changes except in the foveal subfield on day 3 but not on day 1. Red dashed lines indicate BL1
level; center of diamonds represent mean, top and bottom horizontal lines indicate the 95% confidence interval, whiskers indicate standard error and
horizontal lines display standard deviation; n=14.
doi:10.1371/journal.pone.0036155.g004
Table 3. Changes (intra-individual differences) of retinal mean sensitivity (MS) values in all ETDRS subfields at all time-points
measured.
foveal outer-nasal inner-nasal outer-superior inner-superior outer-temporal inner-temporal outer-inferior inner-inferior
BL1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
day1 –0.8560.92 0.0160.11 –0.0260.29 0.1660.78 0.3560.64 0.2460.71 –0.3660.97 –0.3760.72 0.0360.84
day3 –1.3861.12 –0.3560.59 –0.1560.17 0.0760.60 0.1160.56 –0.0960.57 –0.1760.67 –0.2260.28 0.0860.39
BL2 –0.3860.47 0.0260.05 0.1560.42 0.4660.69 0.4860.64 0.2360.60 –0.0860.69 –0.0460.09 0.3260.59
Longitudinal intra-individual changes of retinal mean sensitivity (MS) in all nine ETDRS subfields at each time-point as difference from baseline (BL1).
ETDRS = early treatment of diabetic retinopathy; BL= baseline; data are displayed as mean6standard deviation in dB; n=14.
doi:10.1371/journal.pone.0036155.t003
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resulted in different recording environments such as differences in
air composition between baseline measurements and measure-
ments at high altitude. As SD-OCT measurements in such an
environment have never been performed before, systemic errors
can not entirely be ruled out. However, the bidirectional difference
(i.e. decrease in the foveal subfield vs. increase in extrafoveal
subfields) observed make this unlikely.
In conclusion our present findings indicate that acute exposure
to high altitude related hypoxia does not result in macular edema,
but slight increase in perimacular retinal thickness. These changes
are not associated with changes of central retinal function as
assessed by BCVA and microperimetry and are fully reversible
after descent to lower altitudes. However, with the exception of the
foveal central subfield, the thickness changes at high altitude in the
other subfields are very small and not much different than the
differences between Baselines 1 and 2. Therefore, clinical and/or
biological significance of these findings has to be critically assessed.
For example, it is unclear how such a hypoxic challenge would
affect subjects with existing pathologic changes such as diabetic
retinopathy or how these structures would react to even higher
altitude e.g. during exposure in the Himalayas. Further studies
might be able to define and even predict the associated risk e.g. for
diabetic patients to acute exposure of high altitude related
hypoxia.
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